Search Results - "WANNER, CHRISTOPH"

Sodium Glucose Cotransporter 2 Inhibition and the Visualization of Kidney Hemodynamics by Wanner, Christoph

Get full text

EMPA-REG OUTCOME: The Nephrologist's Point of View by Wanner, Christoph, MD

“…There is increasing evidence that sodium glucose cotransporter 2 (SGLT2) inhibitors have renoprotective effects, as demonstrated by the renal analyses from…”
Get full text

Lipid Management in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2013 Clinical Practice Guideline by TONELLI, Marcello, WANNER, Christoph

“…The Kidney Disease: Improving Global Outcomes (KDIGO) organization developed a clinical practice guideline in 2013 on lipid management and treatment of all…”
Get full text

KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient by Wanner, Christoph, Tonelli, Marcello

“…The Kidney Disease: Improving Global Outcomes (KDIGO) organization developed clinical practice guidelines on lipid management for all adults and children with…”
Get more information

SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases by Wanner, Christoph, Marx, Nikolaus

“…Individuals with diabetes mellitus exhibit an increased propensity to develop cardiovascular disorders such as coronary artery disease, stroke and heart…”
Get full text

The heart and vascular system in dialysis by Wanner, Christoph, Prof, Amann, Kerstin, MD, Shoji, Tetsuo, MD

“…Summary The heart and the vascular tree undergo major structural and functional changes when kidney function declines and renal replacement therapy is…”
Get full text

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure by Packer, Milton, Anker, Stefan D, Butler, Javed, Filippatos, Gerasimos, Pocock, Stuart J, Carson, Peter, Januzzi, James, Verma, Subodh, Tsutsui, Hiroyuki, Brueckmann, Martina, Jamal, Waheed, Kimura, Karen, Schnee, Janet, Zeller, Cordula, Cotton, Daniel, Bocchi, Edimar, Böhm, Michael, Choi, Dong-Ju, Chopra, Vijay, Chuquiure, Eduardo, Giannetti, Nadia, Janssens, Stefan, Zhang, Jian, Gonzalez Juanatey, Jose R, Kaul, Sanjay, Brunner-La Rocca, Hans-Peter, Merkely, Bela, Nicholls, Stephen J, Perrone, Sergio, Pina, Ileana, Ponikowski, Piotr, Sattar, Naveed, Senni, Michele, Seronde, Marie-France, Spinar, Jindrich, Squire, Iain, Taddei, Stefano, Wanner, Christoph, Zannad, Faiez

“…Among patients with heart failure and a reduced ejection fraction, those who received the SGLT2 inhibitor empagliflozin had a significantly lower incidence of…”
Get full text

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial by Inzucchi, Silvio E, Zinman, Bernard, Fitchett, David, Wanner, Christoph, Ferrannini, Ele, Schumacher, Martin, Schmoor, Claudia, Ohneberg, Kristin, Johansen, Odd Erik, George, Jyothis T, Hantel, Stefan, Bluhmki, Erich, Lachin, John M

“…In the BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial involving 7,020 patients with…”
Get full text

Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe by Jager, Kitty J, Kramer, Anneke, Chesnaye, Nicholas C, Couchoud, Cécile, Sánchez-Álvarez, J Emilio, Garneata, Liliana, Collart, Fréderic, Hemmelder, Marc H, Ambühl, Patrice, Kerschbaum, Julia, Legeai, Camille, Del Pino Y Pino, María Dolores, Mircescu, Gabriel, Mazzoleni, Lionel, Hoekstra, Tiny, Winzeler, Rebecca, Mayer, Gert, Stel, Vianda S, Wanner, Christoph, Zoccali, Carmine, Massy, Ziad A

“…The aim of this study was to investigate 28-day mortality after COVID-19 diagnosis in the European kidney replacement therapy population. In addition, we…”
Get more information

Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study by Arends, Maarten, Wanner, Christoph, Hughes, Derralynn, Mehta, Atul, Oder, Daniel, Watkinson, Oliver T, Elliott, Perry M, Linthorst, Gabor E, Wijburg, Frits A, Biegstraaten, Marieke, Hollak, Carla E

“…Fabry disease leads to renal, cardiac, and cerebrovascular manifestations. Phenotypic differences between classically and nonclassically affected patients are…”
Get full text

Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA by Ortiz, Alberto, Cozzolino, Mario, Fliser, Danilo, Fouque, Denis, Goumenos, Dimitrios, Massy, Ziad A, Rosenkranz, Alexander R, Rychlık, Ivan, Soler, Maria Jose, Stevens, Kate, Torra, Roser, Tuglular, Serhan, Wanner, Christoph, Gansevoort, Ron T, Duivenvoorden, Raphaël, Franssen, Casper F M, Hemmelder, Marc H, Hilbrands, Luuk B, Jager, Kitty J, Noordzij, Marlies, Vart, Priya

“…Abstract Diabetes, hypertension and cardiovascular disease have been listed as risk factors for severe coronavirus disease 2019 (COVID-19) since the first…”
Get full text

Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial by Fitchett, David, Butler, Javed, van de Borne, Philippe, Zinman, Bernard, Lachin, John M, Wanner, Christoph, Woerle, Hans J, Hantel, Stefan, George, Jyothis T, Johansen, Odd Erik, Inzucchi, Silvio E

“…Abstract Aims Empagliflozin reduced the risk of cardiovascular (CV) death and heart failure (HF) hospitalizations in patients with type 2 diabetes (T2D) and…”
Get full text

Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence by Rossing, Peter, Caramori, M Luiza, Chan, Juliana C N, Heerspink, Hiddo J L, Hurst, Clint, Khunti, Kamlesh, Liew, Adrian, Michos, Erin D, Navaneethan, Sankar D, Olowu, Wasiu A, Sadusky, Tami, Tandon, Nikhil, Tuttle, Katherine R, Wanner, Christoph, Wilkens, Katy G, Zoungas, Sophia, Craig, Jonathan C, Tunnicliffe, David J, Tonelli, Marcello A, Cheung, Michael, Earley, Amy, de Boer, Ian H

“…The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (CKD) represents a…”
Get more information

GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials by Inker, Lesley A, Heerspink, Hiddo J L, Tighiouart, Hocine, Levey, Andrew S, Coresh, Josef, Gansevoort, Ron T, Simon, Andrew L, Ying, Jian, Beck, Gerald J, Wanner, Christoph, Floege, Jürgen, Li, Philip Kam-Tao, Perkovic, Vlado, Vonesh, Edward F, Greene, Tom

“…Surrogate end points are needed to assess whether treatments are effective in the early stages of CKD. GFR decline leads to kidney failure, but regulators have…”
Get full text

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes by Wanner, Christoph, Inzucchi, Silvio E, Lachin, John M, Fitchett, David, von Eynatten, Maximilian, Mattheus, Michaela, Johansen, Odd Erik, Woerle, Hans J, Broedl, Uli C, Zinman, Bernard

“…Among patients with type 2 diabetes at high cardiovascular risk, the rates of progression of kidney disease and clinically relevant renal events were lower…”
Get full text

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes by Zinman, Bernard, Wanner, Christoph, Lachin, John M, Fitchett, David, Bluhmki, Erich, Hantel, Stefan, Mattheus, Michaela, Devins, Theresa, Johansen, Odd Erik, Woerle, Hans J, Broedl, Uli C, Inzucchi, Silvio E

“…In this study, the addition of empagliflozin, an inhibitor of sodium–glucose cotransporter 2, to standard care reduced cardiovascular morbidity and mortality…”
Get full text

Relation of Burden of Myocardial Fibrosis to Malignant Ventricular Arrhythmias and Outcomes in Fabry Disease by Krämer, Johannes, MD, Niemann, Markus, MD, Störk, Stefan, MD, PhD, Frantz, Stefan, MD, Beer, Meinrad, MD, Ertl, Georg, MD, Wanner, Christoph, MD, Weidemann, Frank, MD

“…The aim of this study was to investigate the impact of myocardial fibrosis in Fabry disease. Seventy-three patients with genetically confirmed Fabry disease…”
Get full text

Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis by Singh, Ajay K, Carroll, Kevin, Perkovic, Vlado, Solomon, Scott, Jha, Vivekanand, Johansen, Kirsten L, Lopes, Renato D, Macdougall, Iain C, Obrador, Gregorio T, Waikar, Sushrut S, Wanner, Christoph, Wheeler, David C, Więcek, Andrzej, Blackorby, Allison, Cizman, Borut, Cobitz, Alexander R, Davies, Rich, Dole, Jo, Kler, Lata, Meadowcroft, Amy M, Zhu, Xinyi, McMurray, John J.V

“…This trial compared the oral HIF-PHI daprodustat with conventional erythropoiesis-stimulating agents for the treatment of anemia in patients with chronic…”
Get full text

CKD Prevalence Varies across the European General Population by Brück, Katharina, Stel, Vianda S, Gambaro, Giovanni, Hallan, Stein, Völzke, Henry, Ärnlöv, Johan, Kastarinen, Mika, Guessous, Idris, Vinhas, José, Stengel, Bénédicte, Brenner, Hermann, Chudek, Jerzy, Romundstad, Solfrid, Tomson, Charles, Gonzalez, Alfonso Otero, Bello, Aminu K, Ferrieres, Jean, Palmieri, Luigi, Browne, Gemma, Capuano, Vincenzo, Van Biesen, Wim, Zoccali, Carmine, Gansevoort, Ron, Navis, Gerjan, Rothenbacher, Dietrich, Ferraro, Pietro Manuel, Nitsch, Dorothea, Wanner, Christoph, Jager, Kitty J

“…CKD prevalence estimation is central to CKD management and prevention planning at the population level. This study estimated CKD prevalence in the European…”
Get full text

Prevention and treatment of protein energy wasting in chronic kidney disease patients: a consensus statement by the International Society of Renal Nutrition and Metabolism by Ikizler, T Alp, Cano, Noel J, Franch, Harold, Fouque, Denis, Himmelfarb, Jonathan, Kalantar-Zadeh, Kamyar, Kuhlmann, Martin K, Stenvinkel, Peter, TerWee, Pieter, Teta, Daniel, Wang, Angela Yee-Moon, Wanner, Christoph

“…Protein energy wasting (PEW) is common in patients with chronic kidney disease (CKD) and is associated with adverse clinical outcomes, especially in…”
Get more information